Suggested remit: To appraise the clinical and cost effectiveness of nivolumab with chemotherapy within its marketing authorisation for treatment of early non-small cell lung cancer.
Status Proposed
Process STA 2018
ID number 3757

Project Team

Project lead Emily Richards

Email enquiries


Key events during the development of the guidance:

Date Update
04 September 2020 The National Institute for Health and Care Excellence (NICE) has been asked to conduct an appraisal of nivolumab with chemotherapy for neoadjuvant treatment of early non-small-cell lung cancer ID3757. We have recently invited stakeholders to respond to a written consultation on the draft scope for this appraisal. On receiving updated regulatory timing information from the company that market nivolumab, NICE has agreed that continuing the scoping exercise at this time would not be appropriate. As a consequence of this we have stopped the scoping exercise for this topic. We apologise for any inconvenience this may cause. Scoping will be rearranged for later date in line with anticipated regulatory approval timings. If you have any comments or concerns please contact the project manager for this proposed appraisal Emily Richards on (44 (0)161 413 4070 or via email on

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance